471 related articles for article (PubMed ID: 20215546)
1. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
LoRusso PM; Boerner SA; Seymour L
Clin Cancer Res; 2010 Mar; 16(6):1710-8. PubMed ID: 20215546
[TBL] [Abstract][Full Text] [Related]
2. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
Dancey JE; Dobbin KK; Groshen S; Jessup JM; Hruszkewycz AH; Koehler M; Parchment R; Ratain MJ; Shankar LK; Stadler WM; True LD; Gravell A; Grever MR;
Clin Cancer Res; 2010 Mar; 16(6):1745-55. PubMed ID: 20215558
[TBL] [Abstract][Full Text] [Related]
3. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
4. Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).
Booth CM; Calvert AH; Giaccone G; Lobbezoo MW; Eisenhauer EA; Seymour LK
Eur J Cancer; 2008 Jan; 44(1):25-9. PubMed ID: 17845846
[TBL] [Abstract][Full Text] [Related]
5. Novel designs and end points for phase II clinical trials.
Adjei AA; Christian M; Ivy P
Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
[TBL] [Abstract][Full Text] [Related]
6. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
7. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
8. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH
Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
[TBL] [Abstract][Full Text] [Related]
9. Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT).
Booth CM; Calvert AH; Giaccone G; Lobbezoo MW; Seymour LK; Eisenhauer EA
Eur J Cancer; 2008 Jan; 44(1):19-24. PubMed ID: 17890079
[TBL] [Abstract][Full Text] [Related]
10. Translation of innovative designs into phase I trials.
Rogatko A; Schoeneck D; Jonas W; Tighiouart M; Khuri FR; Porter A
J Clin Oncol; 2007 Nov; 25(31):4982-6. PubMed ID: 17971597
[TBL] [Abstract][Full Text] [Related]
11. New science-based endpoints to accelerate oncology drug development.
Kelloff GJ; Sigman CC
Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
[TBL] [Abstract][Full Text] [Related]
12. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
[TBL] [Abstract][Full Text] [Related]
13. Selected Proceedings of the NICHD/FDA newborn drug development initiative: Part II.
Giacoia GP; Mattison DR
Clin Ther; 2006 Sep; 28(9):1337-41. PubMed ID: 17062307
[TBL] [Abstract][Full Text] [Related]
14. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
Seymour L; Ivy SP; Sargent D; Spriggs D; Baker L; Rubinstein L; Ratain MJ; Le Blanc M; Stewart D; Crowley J; Groshen S; Humphrey JS; West P; Berry D
Clin Cancer Res; 2010 Mar; 16(6):1764-9. PubMed ID: 20215557
[TBL] [Abstract][Full Text] [Related]
15. Tissue collection for correlative studies in childhood cancer clinical trials: ethical considerations and special imperatives.
Anderson BD; Adamson PC; Weiner SL; McCabe MS; Smith MA
J Clin Oncol; 2004 Dec; 22(23):4846-50. PubMed ID: 15570088
[TBL] [Abstract][Full Text] [Related]
16. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
17. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
18. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
[TBL] [Abstract][Full Text] [Related]
19. Advancing TB vaccines to Phase I clinical trials in the US: regulatory/manufacturing/licensing issues.
Rowland SS; Mayner RL; Barker L
Tuberculosis (Edinb); 2005; 85(1-2):39-46. PubMed ID: 15687026
[TBL] [Abstract][Full Text] [Related]
20. Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute.
Christian MC; Pluda JM; Ho PT; Arbuck SG; Murgo AJ; Sausville EA
Semin Oncol; 1997 Apr; 24(2):219-40. PubMed ID: 9129691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
